Although the discovery of mutant oncoproteins such as FLT-3 ITD, BCR-ABL, and IDH have offered clinically relevant cancer-specific targets; in most cases, cancer metabolic reprograming involves alterations of pathways that occur in nonmalignant cells. This evidence concerns the gene ABL1 and cancer.